Abstract | LEARNING OBJECTIVES: DATA SOURCES: Peer-reviewed articles, selected abstracts from studies presented at recent professional meetings, and the Xopenex [ levalbuterol, (R)- albuterol; Sepracor, Marlborough, MA] Summary Basis of Approval and package insert. STUDY SELECTION: Institutional review board-approved clinical study protocols. RESULTS: CONCLUSIONS:
Levalbuterol seems to provide efficacy and safety advantages in pediatric and adult patients suffering from asthma. Its use may afford a cost benefit as well. More clinical studies are required to extend these observations for use in the treatment of other pulmonary diseases in both adults and children and to determine levalbuterol's impact on long-term therapy of respiratory diseases.
|
Authors | William E Berger |
Journal | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
(Ann Allergy Asthma Immunol)
Vol. 90
Issue 6
Pg. 583-91; quiz 591-2, 659
(Jun 2003)
ISSN: 1081-1206 [Print] United States |
PMID | 12839314
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Adrenergic beta-Agonists
- Bronchodilator Agents
- Albuterol
|
Topics |
- Adrenergic beta-Agonists
(administration & dosage, pharmacology, therapeutic use)
- Adult
- Albuterol
(administration & dosage, pharmacology, therapeutic use)
- Asthma
(drug therapy)
- Bronchodilator Agents
(administration & dosage, pharmacology, therapeutic use)
- Child
- Dose-Response Relationship, Drug
- Humans
- United States
|